The primary aim of the study was to evaluate the incidence of H-ras specific point mutations among a group of Kashmiri patients diagnosed with bladder cancer. We also explored the correlation of clinic-pathological status of the illness with these mutations.
Methods and study design
The DNA samples of both tumor and normal tissue were evaluated for the occurrence of H-ras activating mutations in exon 1 and 2 by PCR-SCCP and DNA sequencing. In addition, blood was also collected from all the cases to rule out any germ-line mutation.
Results
Point mutations of activated H-ras identified in bladder cancer patients were 14.5% (7 of 48), including four transversions (two G→T and two A→T) and three transitions (A→G). Of the mutations, 71.4% were detected in codon 61 and 28.6% in codon 12. The pattern of mutation in the study showed a significant association with smoking in bladder tumors (P <0.05). No correlation was found between tumor grade and/or stage and the presence of H-ras mutation.
Conclusions
Activation of H-ras by mutation plays a less frequent role than other genetic events in the development of the most transitional cell tumors of the bladder in Kashmiri population. Free full text available at www.tumorionline.it
JemalA., SiegelR., WardE.: Cancer statistics 2007. CA Cancer J Clin, 57: 43–66, 2007.
2.
KamaranaN.M., KamatM.R., KurkureA.P.: National Cancer registry project, ICMR; 2000 published in 2003.
3.
DharG.M., ShahG.N., NaheedB.Hafiza: Epidemiological trend in the distribution of cancer in Kashmir Valley. J Epidemiol Commun Health, 47: 290–292, 1993.
4.
DinneyC.P., McConkeyD.J., MillikanR.E.: Focus on bladder cancer. Cancer Cell, 6: 111–116, 2004.
5.
ClavelJ.: Progress in the epidemiological understanding of gene environment interactions in major diseases: cancer. C R Biol, 330: 306–317, 2007.
6.
BosJ.L.: ras oncogenes in human cancer: a review. Cancer Res, 49: 4682–4689, 1989.
7.
TraheyM., McCormickF.: A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science, 238: 542–545, 1987.
8.
ScheffzekK., AhmadianM.R., KabschW., WiesmullerL., LautweinA., SchmitzF., WittinghoferA.: The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science, 277: 333–338, 1997.
9.
BurchillS.A., NealD.E., LunecJ.: Frequency of H-ras mutations in human bladder cancer detected by direct sequencing. Br J Urol, 73: 516–521, 1994.
10.
CzerniakB., DeitchD., SimmonsH., EtkindP., HerzF., KossL.G.: Ha-Ras gene mutation and DNA ploidy in urinary bladder carcinoma. Br J Cancer, 62: 762–763, 1990.
11.
AdelH., JebarA.H., CarolynD.H., DarrenC., TomlinsonI., ColinJ., ClaireF., KnowlesM.A.: FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene, 24: 5218–5225, 2005.
12.
BosariS., MarchettiA., ButtittaF., GrazianiD., BorsaniG., LodaM.: Detection of p53 mutations by single strand conformation polymorphism (SSCP) gel electrophoresis: a comparative study of radioactive and non-radioactive silver-stained SSCP analysis. Diagn Mol Pathol, 4: 249–55, 1995.
13.
CaponD.J., ChenE.Y., LevinsonA.D., SeeburgP.H., GoeddelD.V.: Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature, 302: 33–37, 1983.
14.
RabbaniF., Cordon-CardoC.: Mutation of cell cycle regulators and their impact on superficial bladder cancer. Urol Clin North Am, 27: 83–102, 2000.
15.
SaitoS., HataM., FukuyamaR.: Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. Int J Urol, 4: 178–85, 1997.
16.
FitzgeraldJ.M., RamchurrenN., RiegerK.: Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst, 87: 129–133, 1995.
17.
CzerniakB., CohenG.L., EtkindP.: Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum Pathol, 23: 1199–12041, 992.
18.
JebarA.H., HurstC.D., TomlinsonD.C., JohnstonC., TaylorC.F., KnowlesM.A.: FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene, 24: 5218–5125, 2005.
19.
SidranskyD., Von EschenbachA., TsaiY.C., JonesP., Summer-hayesI., MarshallF., PaulM., GreenP., HamiltonS.R., FrostP., VogelsteinB.: Identification of p53 gene mutations in bladder cancers and urine samples. Science, 252: 706–709, 1991.
20.
HartgeP., SilvermanD., HooverR., SchairerC., AltmanR., AustinD., CantorK., ChildM., KeyC., MarrenL.D., MasonT.J., MeigsJ.W., MyersM.H., NarayanaA., SullivanJ.W., SwansonG.M., ThomasD., WestD.: Changing cigarette habits and bladder cancer risk; a case-control study. J Nati Cancer Inst, 78: 1119–1125, 1987.
21.
SlebosR.J., HrubanR.H., DalesioO., MooiW.J., OfferhausG.J., RodenhuisS.: K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst, 83: 1024–1027, 1991.
22.
HabuchiT., TakahashiR., YamadaH.: Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res, 53: 3795–3799, 1993.
23.
ClavelJ.: Progress in the epidemiological understanding of gene environment interactions in major diseases: cancer. C R Biol, 330: 306–317, 2007.
24.
JebarA.H., HurstC.D., TomlinsonD.C.: FGFR3 and ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene, 24: 5218–5225, 2005.
25.
TheodorescuD., CornilI., SheehanC., ManM.S., KerbelR.S.: Ha-ras induction of the invasive phenotype results in upregulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. Cancer Res, 51: 4486–4491, 1991.
26.
ZhangZ.T., PakJ., HuangH.Y., ShapiroE., SunT.T., PellicerA., WuX.R.: Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene, 20: 1973–1980, 1991.
